<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> is a disease of increasing prevalence in the general population and of unknown cause </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> is manifested as <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> due to a relative deficiency of the production of insulin by the pancreatic beta-cells </plain></SENT>
<SENT sid="2" pm="."><plain>One determinant in the development of <z:mp ids='MP_0002055'>diabetes</z:mp> is an inadequate mass of beta-cells, either absolute (type 1, <z:mp ids='MP_0002056'>juvenile diabetes</z:mp>) or relative (type 2, maturity-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp>) </plain></SENT>
<SENT sid="3" pm="."><plain>Earlier, we reported that the intestinal hormone glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> I (GLP-I) effectively augments <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion </plain></SENT>
<SENT sid="4" pm="."><plain>Here we report that exendin-4, a long-acting GLP-I <z:chebi fb="4" ids="48705">agonist</z:chebi>, stimulates both the differentiation of beta-cells from ductal progenitor cells (neogenesis) and proliferation of beta-cells when administered to rats </plain></SENT>
<SENT sid="5" pm="."><plain>In a partial pancreatectomy rat model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the daily administration of exendin-4 for 10 days post-pancreatectomy attenuates the development of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>We show that exendin-4 stimulates the regeneration of the pancreas and expansion of beta-cell mass by processes of both neogenesis and proliferation of beta-cells </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, GLP-I and analogs thereof hold promise as a novel therapy to stimulate beta-cell growth and differentiation when administered to diabetic individuals with reduced beta-cell mass </plain></SENT>
</text></document>